| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 12.3 | 10.1 |
| Gross profit | 8.8 | 6.4 |
| Profit before tax | -4.1 | -3.5 |
| Net income | -4.2 | -3.7 |
| EPS (diluted, $ a share) | $-0.10 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +22.2% |
|---|---|
| Gross margin | 71.3% |
| Operating margin | -14.0% |
10-Q filed with the SEC, NYSE: MYO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Myomo, Inc.: key numbers
- Share price
- $1.02Close, Nov 16
- Market cap
- $40.9M
- Shares outstanding
- 40.1MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Myomo, Inc.
All →Myomo Financial Results
Myomo reported record third-quarter revenue of $12.3 million, a 22% year-over-year increase driven by a shift toward recurring patient sources. The company achieved breakeven Adjusted EBITDA and narrowed its full-year 2026 revenue guidance to the upper end of its previous range.
- Term
- Q3 2026
“The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA and sequentially lower cash burn.”
Paul R. Gudonis, Chairman and Chief Executive Officer